What Is the IDNA ETF? A Complete Guide to Returns, Fees, Holdings, and Alternative ETFs
The iShares Genomics Immunology and Healthcare ETF (IDNA) is a global healthcare ETF focused on companies driving innovation in genomic analysis, immunotherapy, and bioengineering. Key selection criteria include its thematic concentration relative to broad healthcare funds, its expense ratio, its dividends, and its volatility.
SubscribeWhat Is the iShares Genomics Immunology and Healthcare ETF?
This is a thematic healthcare ETF that tracks an index of innovative companies in genomics, immunology, and bioengineering. It holds a broad range of related companies listed in developed and emerging markets, weighted by market capitalization.
It suits long-term, growth-oriented investors who want concentrated exposure to innovation themes such as genomics and immunotherapy within healthcare.
It is a passive (index-tracking) ETF managed by BlackRock (iShares).
How Does the iShares Genomics Immunology and Healthcare ETF Invest?
| Item | Details |
|---|---|
| Tracked index | Genomics, immunology, and healthcare theme index |
| Management style | Passive (index tracking) |
| Rebalancing frequency | Semiannual |
| Dividend frequency | Semiannual dividends |
| Issuer | BlackRock (iShares) |
| Total expense ratio | 0.47% |
By tracking the index constituents, the fund allocates most of its assets to innovative companies in genomics, immunology, and biotechnology. It focuses on the global healthcare innovation theme across developed and emerging markets, and changes in its holdings are reflected through semiannual rebalancing.
- Concentrated global exposure to the genomics and immunotherapy themes
- Includes innovative companies from both developed and emerging markets
iShares Genomics Immunology and Healthcare ETF Size and Costs (AUM and Expense Ratio)
Assets under management (AUM) stand at $330.6M, and the total expense ratio (Expense Ratio) is 0.47% per year.
Its thematic concentration is higher than that of broad healthcare ETFs, so volatility also tends to be larger.
iShares Genomics Immunology and Healthcare ETF Performance and Trends
1-Year Price Performance
Dividend & Yield
52-Week Price RangeThe biotech and genomics theme tends to react sensitively to new drug pipeline expectations and the interest rate environment, so its trend volatility is relatively large. It has tended to show strength when expectations for innovation rise and weakness when investors turn risk averse.
As is typical of thematic ETFs, fund flows tend to swing between inflows and outflows depending on market interest in biotech and healthcare innovation. Its asset base falls into the small to mid-sized category compared with broad healthcare core ETFs.
iShares Genomics Immunology and Healthcare ETF Pros and Cons
Its strength is concentrated exposure to the genomics and immunology innovation theme, while its weaknesses are the volatility that comes with thematic concentration and the risk of emerging market exposure.
💪 Key Strengths
⚠️ Points to Watch
iShares Genomics Immunology and Healthcare ETF Alternative ETFs and Related Products
BBH, MEDX, MEDI, GDOC, and JDOC, which appear in the table as comparison targets in the same healthcare category, differ in their biotech and healthcare sub-themes and in their management approach. Direct substitutes outside the table that are worth considering include ARKG for the genomics theme, XLV as a broad healthcare core ETF, and IBB for exposure across biotech.
Peer Comparison ETFs| Ticker | Name | Price | Change | AUM | Total Expense Ratio | Dividend Yield | 1Y |
|---|---|---|---|---|---|---|---|
 BBH | VanEck Biotech ETF | $253.27 | +1.4% | $508.5M | 0.35% | 0.38% | +42.5% |
 MEDI | Harbor Health Care ETF | $34.24 | +1.1% | $44.1M | 0.80% | 0.04% | +13.5% |
 GDOC | Goldman Sachs Future Health Care Equity ETF | $38.15 | +0.8% | $19.9M | 0.75% | 0.3% | +11.1% |
 MEDX | Horizon Kinetics Medical ETF | $37.13 | +0.7% | $17.3M | 0.85% | 1.1% | +19.0% |
 JDOC | JPMorgan Healthcare Leaders ETF | $64.05 | +0.3% | $9.6M | 0.65% | 0.8% | +15.9% |
Top Holdings| Ticker | Name | Weight | Price | Change | Market Cap | P/E | Dividend Yield |
|---|---|---|---|---|---|---|---|
| RVMD | Revolution Medicines Inc | 0.11% | $188.72 | +1.3% | $40.4B | - | - |
| MRNA | Moderna Inc | 0.10% | $214.16 | +3.0% | $85.5B | - | - |
 TWST | Twist Bioscience Corp | 0.05% | $173.45 | +8.5% | $11.4B | - | - |
| REGN | Regeneron Pharmaceuticals Inc | 0.04% | $813.27 | -0.3% | $83.7B | 20.1 | 0.44% |
 INCY | Incyte Corp | 0.04% | $116.87 | +0.2% | $23.7B | 14.9 | - |
| TAK | Takeda Pharmaceutical Co ADR | 0.04% | $20.15 | -0.6% | $64.1B | - | 3.19% |
| MRK | Merck & Co Inc | 0.04% | $140.93 | -0.6% | $347.7B | 112.6 | 2.42% |
 BNTX | BioNTech SE ADR | 0.04% | $87.99 | +1.1% | $22.1B | - | - |
iShares Genomics Immunology and Healthcare ETF Investor Checkpoints
Here are the points to review before investing in IDNA. Because this ETF focuses on innovation themes within healthcare, it is worth checking volatility, costs, and exchange rates in advance.
| Checkpoint | What to check | Current status |
|---|---|---|
| 💵 Expense ratio | Check the impact of cumulative costs over a long holding period | Annual fee applies |
| 📊 Theme concentration | Volatility trend relative to broad healthcare | High concentration |
| 🌏 Regional exposure | Check the weighting of developed and emerging markets | Global diversification |
| 💱 Exchange rate | Impact on returns converted into won | Not currency hedged |
The main risk factors are the high volatility that comes with thematic concentration and the clinical trial and regulatory risks for new drugs. In risk-averse phases, drawdowns can be larger than those of broad healthcare ETFs.
It is a suitable choice for investors who want long-term exposure to the genomics and immunotherapy innovation theme. If stable core exposure to healthcare overall is the priority, consider XLV, and if you want to diversify across biotech, consider an ETF such as IBB.
SubscribeDisclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.
This article reflects information as of June 23, 2026.
Today's 5 AI picks, all free